The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Abstract
BACKGROUND: Few options for transplantation currently exist for patients highly sensitized to HLA. This exploratory, open-label, phase 1-2, single-center study examined whether intravenous immune globulin plus rituximab could reduce anti-HLA antibody levels and improve transplantation rates. METHODS: Between September 2005 and May 2007, a total of 20 highly sensitized patients (with a mean [+/-SD] T-cell panel-reactive antibody level, determined by use of the complement-dependent cytotoxicity assay, of 77+/-19% or with donor-specific antibodies) were enrolled and received treatment with intravenous immune globulin and rituximab. We recorded rates of transplantation, panel-reactive antibody levels, cross-matching results at the time of transplantation, survival of patients and grafts, acute rejection episodes, serum creatinine values, adverse events and serious adverse events, and immunologic factors. RESULTS: The mean panel-reactive antibody level was 44+/-30% after the second infusion of intravenous immune globulin (P<0.001 for the comparison with the pretreatment level). At study entry, the mean time on dialysis among recipients of a transplant from a deceased donor was 144+/-89 months (range, 60 to 324). However, the time to transplantation after desensitization was 5+/-6 months (range, 2 to 18). Sixteen of the 20 patients (80%) received a transplant. At 12 months, the mean serum creatinine level was 1.5+/-1.1 mg per deciliter (133+/-97 micromol per liter), and the mean survival rates of patients and grafts were 100% and 94%, respectively. There were no infusion-related adverse events or serious adverse events during the study. Long-term monitoring for infectious complications and neurologic problems revealed no unanticipated events. CONCLUSIONS: These findings suggest that the combination of intravenous immune globulin and rituximab may prove effective as a desensitization regimen for patients awaiting a transplant from either a living donor or a deceased donor. Larger and longer trials are needed to evaluate the clinical efficacy and safety of this approach. (ClinicalTrials.gov number, NCT00642655.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
The Quality of Life of Patients with End-Stage Renal Disease
Evans, R. W., Manninen, D. L., Garrison, L. P., Hart, L. G., Blagg, C. R., Gutman, R. A., Hull, A. R., & Lowrie, E. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120905 · Cited by 1,183
Solez, K., Colvin, R., Racusen, L., Sis, B., Halloran, P., Birk, P., Campbell, P., Cascalho, M., Collins, A., Demetris, A., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01688.x · Cited by 1,082
Comparison of Survival Probabilities for Dialysis Patients vs Cadaveric Renal Transplant Recipients
Port, F. K. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510110079036 · Cited by 825
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Ahmed, A. R., Spigelman, Z., Cavacini, L. A., & Posner, M. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062930 · Cited by 456
Jordan, S. C., Tyan, D., Stablein, D., McIntosh, M., Rose, S., Vo, A., Toyoda, M., Davis, C., Shapiro, R., Adey, D., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000145878.92906.9f · Cited by 435
Self-citationTreatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Stockman, J. A. (2008) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(08)70301-4 · Cited by 404
Gebel, H. M., Bray, R. A., & Nickerson, P. (2003) · American Journal of Transplantation · doi:10.1046/j.1600-6135.2003.00273.x · Cited by 362
Vieira, C. A., Agarwal, A., Book, B. K., Sidner, R. A., Bearden, C. M., Gebel, H. M., Roggero, A. L., Fineberg, N. S., Taber, T., Kraus, M. A., et al. (2004) · Transplantation · doi:10.1097/01.tp.0000112934.12622.2b · Cited by 271
Rituximab Therapy for Acute Humoral Rejection After Kidney Transplantation
Faguer, S., Kamar, N., Guilbeaud-Frugier, C., Fort, M., Modesto, A., Mari, A., Ribes, D., Cointault, O., Lavayssière, L., Guitard, J., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000261113.30757.d1 · Cited by 211
Jordan, S. C., Vo, A. A., Peng, A., Toyoda, M., & Tyan, D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01214.x · Cited by 180
Self-citationDrug Insight: rituximab in renal disease and transplantation
Salama, A. D., & Pusey, C. D. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0133 · Cited by 129
THE FLOW CYTOMETRIC CROSSMATCH
Bray, R. A., Lebeck, L. K., & Gebel, H. M. (1989) · Transplantation · doi:10.1097/00007890-198911000-00022 · Cited by 124
Current approaches to treatment of antibody‐mediated rejection
Jordan, S. C., Vo, A. A., Tyan, D. B., Nast, C. C., & Toyoda, M. (2005) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2005.00363.x · Cited by 99
Self-citationVo, A. A., Wechsler, E., Wang, J., Peng, A., Toyoda, M., Lukovsky, M., Reinsmoen, N. L., & Jordan, S. C. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02017.x · Cited by 62
Self-citation
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Levey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
Costanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Lefaucheur, C., Loupy, A., Hill, G. S., Andrade, J., Nochy, D., Antoine, C., Gautreau, C., Charron, D., Glotz, D., & Suberbielle-Boissel, C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101065 · Cited by 789
Metadata
- Authors
- Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-17
- Volume
- 359
- Issue
- 3
- Pages
- 242-251
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139856839
- Cited by
- 692
- References
- 18
- FWCI
- 46.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.